Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | NDI-101150 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NDI-101150 | NDI 101150|NDI101150 | Limited information is currently available on NDI-101150, a putative MAP4K1 (HPK1) inhibitor (Mar 2022). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05128487 | Phase Ib/II | NDI-101150 NDI-101150 + Pembrolizumab | A Study of NDI 1150-101 in Patients With Solid Tumors | Recruiting | USA | 0 |